RecruitingNot ApplicableNCT06511141
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Sacral Neuromodulation for Male Overactive Bladder
Sponsor
Axonics, Inc.
Enrollment
150 participants
Start Date
Oct 22, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Eligibility
Sex: MALEMin Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is evaluating sacral neuromodulation (a small implanted device that sends mild electrical signals to the nerves controlling the bladder) as a treatment for overactive bladder (OAB) in men — a condition causing urgent and frequent urges to urinate, or leaking urine before reaching the toilet.
**You may be eligible if...**
- You are a male aged 18 or older
- You have been diagnosed with overactive bladder (with urgency incontinence or urinary frequency as your primary problem)
- You are willing to complete bladder diaries and questionnaires
- You are able to attend all follow-up visits for up to one year
**You may NOT be eligible if...**
- You have had prostate surgery or a prostate procedure in the past 6 months
- Your doctor determines you are not a suitable candidate
- You have other conditions that prevent participation
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICEAxonics SNM System
To assess clinical outcomes of the Axonics SNM System in the male OAB population.
Locations(20)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06511141
Related Trials
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
NCT046926751 location
DESTINY-PANTUMOUR04
NCT0712400017 locations
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT0700515433 locations
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System
NCT068073593 locations
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
NCT0733644618 locations